03:22 PM EDT, 08/08/2025 (MT Newswires) -- Gilead Sciences' ( GILD ) recently launched HIV prevention drug Yeztugo is unlikely to generate any significant financial impact until 2028, Oppenheimer said in a note emailed Friday.

The brokerage said it sees revenue growth for the biopharmaceutical company of 5% to 6% by 2028, primarily driven by antibody-drug conjugate Trodelvy's 1L expansion and anito-cel's launch and not due to Yeztugo.

Oppenheimer analysts, however, said "enthusiasm" around pre-exposure prophylaxis, a medical strategy for HIV prevention, could not have come at a better time, as patients have started to receive Yeztugo twice a year.

A regulatory decision from the US Food and Drug Administration, expected in 2026, has the potential to twofold Trodelvy's addressable patient size, analysts added.

Oppenheimer raised its price target on the company to $128 from $125 and maintained its outperform rating.

Shares of the company were up 8% in recent trading.

Price: 119.15, Change: +8.87, Percent Change: +8.04